FDA AI devices lack routine gender-specific data; Adil Haider joins surgeons’ educator academy
Healthcare AI is advancing from pilots into production, medical education and clinical innovation, but the evidence base remains uneven. Adil Haider’s new role highlights efforts to train surgeons for AI-enabled care, while the FDA analysis shows that sex-specific validation and broader clinical transparency have not kept pace; clinical evidence, privacy, cybersecurity and human oversight remain key issues to watch.
Saturday, Sep 19, 2026
Tracking: Medicine Robotics · AI Medicine · AI Healthcare
FDA rules leave sex-specific validation gap in AI medical devices
An analysis published September 17, 2026, highlights a persistent weakness in the U.S. medical-AI pipeline: FDA authorization generally does not require developers to validate performance separately across female and male patients.
TechTimes reports that fewer than one-third of 903 FDA-authorized AI devices through August 2024 supplied sex-specific clinical data; nearly one-quarter of submissions reported no clinical performance study.
The finding lands as companies push AI into regulated healthcare.
Scale’s September 17 job posting for a healthcare-and-life-sciences solutions engineering lead says providers, payers, pharmaceutical and biotech firms, and medical-device companies are moving systems from pilots to production while seeking help with clinical and compliance questions.
Together, the reports point to a deployment market expanding faster than transparency about who these systems work for.
Key facts:
Fewer than one-third of 903 FDA-authorized devices provided sex-specific clinical data.
Nearly one-quarter of submissions reported no clinical performance study.
FDA authorized 168 machine-learning Class II devices in 2024.
Scale advertised a healthcare AI solutions-engineering lead on September 17.
Only 15.5% of 2024 devices provided demographic performance data.
Why it matters: For healthcare buyers, authorization alone may not show whether an AI system performs consistently across patient groups.
The article links underrepresentation in training data to weaker performance when models are applied to underrepresented populations, including women.
Scale’s hiring push suggests that clinical validation and compliance expertise are becoming part of AI deployment, not merely research.
The next watchpoint is whether FDA review, procurement standards, or provider deployment practices begin demanding demographic performance data before systems enter routine care.
Carle Illinois AI Chief Joins Surgeons’ Educator Academy
Adil H. Haider, Carle Illinois College of Medicine’s inaugural Chief Artificial Intelligence Officer, has been inducted into the American College of Surgeons Academy of Master Surgeon Educators.
The recognition follows his work leading the college’s strategy for developing and responsibly deploying AI across medical education, translational research and clinical innovation.
Haider was inducted in Chicago on September 10 and participated the following day in an Academy symposium on training the surgical workforce of tomorrow.
He joined a panel on future surgeon training and chaired a session on AI applications in surgical education.
The move comes as healthcare leaders debate how quickly AI should enter clinical practice: HealthTech Magazine argues that diagnosis, treatment selection and monitoring may deliver earlier benefits than AI-created drugs, but only with clinical validation, privacy protections, cybersecurity, regulation and human oversight.
Key facts:
Adil H. Haider joined the ACS Academy of Master Surgeon Educators in 2026.
Haider became Carle Illinois College of Medicine’s inaugural Chief AI Officer in 2026.
He chaired a September 11 session on AI applications in surgical training.
HealthTech Magazine identifies diagnosis, treatment selection and monitoring as likely early AI gains.
AI performance in controlled settings does not guarantee readiness for diverse patients.
Why it matters: Haider’s recognition connects AI leadership with the education and oversight of future surgeons, rather than treating clinical AI as a purely technical rollout.
His symposium role also places ethical and effective use of AI in surgical training alongside broader workforce planning.
For healthcare providers, the practical message is cautious adoption: AI can help integrate records, imaging, biomarkers and treatment histories, but clinicians must still validate outputs and apply judgment.
Organizations that want personalized care will also need stronger data quality, privacy, security and governance before scaling these systems.